tbuckley/cabot-search huggingface dataset:
Alteration of HER2 functional profiling over time in patients with metastatic breast cancer (MBC).
Authors: Y. Wu, P. Kim, L. Liu, T. Lee, G. Harvie, K. Magonova, J. Gregorian, P. Shin, S. Singh, J. N. Lowder
Journal: Journal of Clinical Oncology (2010)

e21002 Background: Breast cancer patients with HER2 over-expression/amplification are associated with shorter time to relapse and shorter disease-free and overall survival. 15-20% of breast cancers are HER2-positive by IHC or FISH. Changes in HER2 status between primary and metastatic tumors have been reported to occur and assessing this might have therapeutic impact. Methods: 50 female patients with stage IIIB-IV MBC (baseline age 57±13yr) of various primary ER/PR/HER2 status, determined by IHC staining, were enrolled and followed up to 14 weeks where they received various MBC therapies per their physician's discretion. Whole blood samples were collected at three study visits, 5-7 weeks apart from each other, for isolation of CTCs. The serial CTCs were counted using the Varidex method and tested for expression and phosphorylation (activation) of HER1, HER2, and CK, using a novel multiplexed microarray (Collaborative Proximity Immunoassay, COPIA). This platform has been developed to enable the profiling of the target proteins in signal transduction pathways at high levels of sensitivity and specificity. Radiographic tumor assessments were conducted at the 2nd and 3rd visits. Results: In primary IHC-HER2 negative breast tumors, 30% were HER2 over-expressed (tHER2+) and 56% were HER2 activated (pHER2+) in CTCs before initiating a new therapy. CTCs ≥5 were observed in 37% of patients and CK levels correlated with cell counts. Patients with no detectable CTCs or CTCs <5 had unpredictable levels of CK, however HER2 expression or activation was detected in CTCs in 31% and 47% of those patients, respectively. 87% of the patients with CTCs ≥5 had an IHC-HER2 negative primary tumor, 11 out of 15 patients (73%) were ER/PR positive. 13% of the patients with CTCs ≥5 had IHC-HER2 positive primary tumors, all were ER/PR negative. Conclusions: HER2 status can be measured in CTCs with COPIA. Alteration of HER2 functional profiling over time in patients with MBC has been observed. Continued investigations on CTCs as a potential source of tissue for prognosis and diagnosis profiling are warranted. No significant financial relationships to disclose.
Lipocalin-2 Gene and its Protein Neutrophil Gelatinase-Associated Lipocalin are Biomarkers of Acute-On-Chronic Liver Failure
Authors: I. Graupera, M. Coll, M. Llopis, X. Ariza, E. Solà, P. Huelin, C. Solé, E. Pose, C. Millán, R. Moreira, G. de Prada, D. Blaya, D. Rodrigo, L. Perea, B. Aguilar, P. Sancho-Bru, P. Ginés
Journal: Journal of Hepatology (2016)
O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations
Authors: Philip C. Mack, Kimberly C. Banks, Oliver A. Zill, Stefanie A. Mortimer, Darya I. Chudova, Justin Odegaard, Christine E. Lee, Rebecca J. Nagy, Helmy Eltoukhy, Amirali Talasaz, Richard Lanman, David R. Gandara
Journal: Journal of Thoracic Oncology (2016)
Abstract 17296: Autonomic Dysfunction in Metabolic Syndrome With Normal Blood Pressure is Associated With Exacerbate Response of Blood Pressure During Maximal Exercise
Authors: Akothirene C Dutra-Marques, Felipe X Cepeda, Sara Rodrigues, Jefferson C Carvalho, Edgar Toschi-Dias, Camila Jordão, Maria U Rondon, Maria J Alves, Ivani C Trombetta
Journal: Circulation (2015)

Introduction: Hypertensive patients presented impairment in the blood pressure (BP) response during maximal exercise test. Sympathetic hyperactivation and decreased baroreflex sensitivity (BRS) are involved in the progression of metabolic syndrome (MetS) in cardiovascular disease. Hypothesis: (1) MetS patients with normal level of clinical BP show exaggerate peak and recovery systolic BP in response to maximal exercise; (2) Muscle sympathetic nerve activity (MSNA) and BRS are associated with these impairments. Methods: We selected MetS (ATP III) patients with normal BP (ASH/ISH criteria; MetS= 27, 46±1 y) and a healthy control group without MetS (C= 19, 48±2 y). We evaluated MSNA(microneurography), BRS (spontaneous BP and HR fluctuations) and auscultatory BP measures at pretest, peak, 1 st , 2 nd , 4 th min of recovery during cardiopulmonary exercise test. Results: Compared to C, MetS had higher BMI and impairment in all MetS risk factors. MetS had higher BP at pretest, peak, 1 st , 2 nd , 4 th min of recovery (P&lt;0.05). Interestingly, we found that even MetS patients with normal BP had lower spontaneous BRS for decreases (9.38 + 0.7 vs. 12.33 + 1.25 msec/mmHg, P=0.03) and higher levels of MSNA (27 + 1 vs. 18 + 1 bursts/min, P&lt;0.001) compared to C. Further analyses showed association between BRS for decreases with peak BP (r=-.32; P=0.04). Moreover, the MSNA had association with peak BP (r=.40; P=0.03) and BP at 1 st min of recovery (r=.48; P=0.01). Fascinatingly, a subgroup of MetS patients with normal BP but exaggerate peak BP (systolic BP &gt;190 mmHg for women and &gt;210 mmHg for men) showed strong association between BRS for decreases with peak BP (r=-.70; P&lt;0.02) and BRS for decreases with BP at 1 st min of recovery (r=-.73; P&lt;0.04). Conclusion: MetS patients even with normal BP, already show sympathetic hyperactivity and decreased baroreflex sensitivity which could explain, at least in part, the exacerbated BP response during maximal exercise.
Spontaneous Cerebral Hemorrhage and Sudden Biventricular Failure After Lung Transplantation
Authors: Ankit Bharat, Hector Cajigas, G. R. Scott Budinger
Journal: JAMA Cardiology (2016)

A woman with end-stage lung disease secondary to systemic sclerosis and pulmonary hypertension underwent bilateral sequential lung transplantation without cardiopulmonary bypass through a clamshell thoracotomy and after the operation developed seizures when ambulating. What is your diagnosis?
Characteristics of Fecal Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients: Aconnection between Endotoxin and NAFLD
Authors: T. Kessoku, K. Imajo, Y. Honda, Y. Ogawa, T. Kato, H. Endo, K. Wada, A. Nakajima
Journal: Journal of Hepatology (2016)
THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE
Authors: Kenneth Goodner, Frank L. Horsfall
Journal: The Journal of Experimental Medicine (1936)

1. Type I antipneumococcus horse serum, in amounts exceeding a characteristic optimum, fails to protect mice against infection with the homologous type pneumococci. This failure is due to a marked inhibition of the phagocytic mechanism in the earlier stages of the infectious process. On the other hand, antipneumococcus rabbit serum in similar quantities does not inhibit phagocytosis, nor does it block the protection. 2. The experimental evidence suggests that the prozoning action of immune horse serum is due primarily to some characteristic property of the specific antibody and secondarily to an heterologous component of the serum, ineffective in itself but acting through the mediation of the antigen-antibody combination. This secondary factor may be a lipid.
Simvastatin Impedes the Endotoxin-Induced Aggravation of Hepatic Microvascular Dysfunction in Two Animal Models of Liver Cirrhosis
Authors: D.M. Tripathi, E. Lafoz, H. Garcia-Caldero, J.C. Garcia-Pagan, J. Gracia-Sancho, J. Bosch
Journal: Journal of Hepatology (2016)
The impact of delirium recollection (DR) on the level of distress in patients (P) with advanced cancer and their family caregivers (CG)
Authors: E. Bruera, J. Willey, T. Paraskevopoulos, Z. Li, E. Del Fabbro, D. S. Zhokovsky, J. Marriott, J. L. Palmer
Journal: Journal of Clinical Oncology (2008)

9529 Background: Delirium is the most frequent neuro-psychiatric complication in patients with advanced cancer. The frequency of DR and its impact on P and CG distress level are not well understood. Method: In this exploratory study, we included inpatient with advanced cancer who completely recovered from an acute delirium episode within 3 days (Memorial Delirium Assessment Scale <13), and their CG who were at bedside during delirium. The Delirium Experience Questionnaire was conducted in P. In addition, we assessed recall of specific delirium symptoms and related distress in P, CG, bedside nurse (RN) and palliative care specialist (PCS). Results: A total of 99 P/CG dyads participated in the study. Delirium subtype included hypoactive (20%), hyperactive (13%) and mixed (67%). DR in 99 patients included confusion (73%), time disorientation (58%), psychomotor agitation (56%), space disorientation (53%), delusion (33%) and hallucinations (visual 51%, auditory 18%, and tactile 12%). There was significant univariate association (p<0.005) between total distress score and delirium symptoms (time and place disorientation, visual, tactile and auditory hallucinations, delusions and psychomotor agitation, respectively). Multivariate analysis showed place disorientation and visual hallucinations were not independently associated with total distress scores; other symptoms remain significant (R2 = 0.62). Median (Q1-Q3) distress (0=no, 4=extreme) was 2 (1–3) for P, vs 3 for CG (1–3, p<0.001), 0 for RN (0–3, p<0.001), and 0 for PCS (1–3, p<0.001). Psychomotor agitation was the most distressing symptom for CG, while psychomotor agitation and tactile hallucinations were the most distressing for P. Weighted Kappa showed significant agreement in 7/8 delirium symptoms between P and CG (p< 0.001), 2/8 between P and RN (p <0.05). No significant agreement was observed between P and PCS. Conclusions: Most P had DR that resulted in moderate to severe distress in P and CG. CG significantly overrated distress, and RN and PCS significantly underrated distress as compared to P. Research on early and more aggressive pharmacological management of delirium and improved psychosocial support to reduce P and CG distress level are needed. No significant financial relationships to disclose.
Urine Albumin-To-Creatinine Ratio is Associated with the Severity of Liver Disease, Renal Function and Survival in Patients with Decompensated Cirrhosis
Authors: E. Cholongitas, I. Goulis, M. Ioannidou, S. Soulaidopoulos, P. Chalevas, E. Akriviadis
Journal: Journal of Hepatology (2016)
Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530
Authors: T. Ng, T. Pilot-Matias, R. Tripathi, G. Schnell, T. Reisch, J. Beyer, T. Dekhtyar, S. Wang, F. Mensa, J. Kort, C. Collins
Journal: Journal of Hepatology (2016)
Targeting HMGB1 Increased the Sensitivity of MM Cells to Chemotherapy
Authors: Xing Guo, Donghua He, Jing Chen, Li Yang, Yi Li, Qingxiao Chen, Jingsong He, Yang Yang, Enfan Zhang, Wenjun Wu, Xiaoyan Han, Gaofeng Zheng, Yi Zhao, He Huang, Zhen Cai
Journal: Blood (2014)
Epigallochatechin Gallate Stimulates the Expression of the MIRNAS, MIR-122, -200c, -155 and -182 and Decreases Viral Entry in HCV Infected Cells through Repressing Tight Junction Proteins, Occludin and Claudin-1
Authors: S.E. Riad, D.S. Elhelw, G. Esmat, A.I. Abdelaziz
Journal: Journal of Hepatology (2016)
Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer.
Authors: B. Chibaudel, C. Tournigand, F. Bonnetain, T. Andre, G. Lledo, F. Maindrault-Goebel, A. K. Larsen, C. Louvet, A. de Gramont
Journal: Journal of Clinical Oncology (2010)

3577 Background: Three risk groups have been identified in patients with 5-fluorouracil- (5-FU) based treatment for metastatic colorectal cancer, depending on four baseline prognostic parameters: WHO performance status (PS), white blood cell (WBC) count, alkaline phosphatase and number of metastatic sites. There is some evidence to indicate that WHO PS and lactico dehydrogenase (LDH) level at baseline are the strongest parameters associated with poor prognosis in recent trials with oxaliplatin-based or irinotecan-based first-line chemotherapy. Methods: A total of 803 patients treated with FOLFOX or FOLFIRI in 3 prospective trials were randomly separated into learning (n = 535) and validation (n = 268) samples. Survivals were estimated using Kaplan Meier method and the log-rank test was used to compare the curves. The Cox regression model was used for multivariate analysis of prognostic factors for survival. Results: Independent prognostic factors identified in multivariate analysis for overall survival were performance status, LDH, and APL. Three risk groups could be identified: low risk group with WHO PS 0 and normal LDH level (n = 174; median OS 29.2 months), intermediate risk group with WHO PS 0 and increased LDH level or WHO PS 1 and normal LDH level (n = 202; median OS 19.8 months), and a high risk group with WHO PS 1 and increased LDH level or WHO PS 2 (n = 159; median OS 13.6 months). Median survival for the good, intermediate and high risk groups in validation sample were 31.7 months, 20.7 months, and 13.8 months, respectively. Conclusions: We identified three risk groups for death depending on 2 baseline parameters WHO PS and LDH level. This prognostic model can be useful for patients stratification in future clinical trials. No significant financial relationships to disclose.
Inhibition of human head and neck squamous cell cancer growth by modulation of heat shock proteins and induction of the mitochondrial apoptotic pathway with withaferin A
Authors: M. S. Cohen, B. N. Timmermann, G. O'Donnell, A. K. Samadi
Journal: Journal of Clinical Oncology (2009)

e17003 Background: Epithelial cancers, particularly lung cancer and head and neck squamous cell carcinoma (HNSCC), continue to pose formidable challenges in clinical practice. Novel chemotherapeutic agents have been developed, but even those have limited long-term benefits in the treatment of these tumors, illustrating the need to continue to improve systemic therapy for affected patients. The objective of the present study was to investigate the effect of withaferin A (WA), a plant-derived small molecule, on cancer cell growth, heat shock protein expression and induction of apoptosis in human HNSCCs. Methods: MDA1986 and JMAR HNSCC cells were used in all experiments. The effect of WA on cell viability was determined by MTS assay. Apoptosis and mitochondrial membrane potential changes were assessed by annexin V/propidium iodide and JC-1 staining respectively using standard flow cytometry methods. Effect of WA on modulation of heat shock proteins was determined by Western blot analysis. Results: Withaferin A reduces cell viability in both MDA1986 and JMAR cells with IC50 levels of 265 ± 5 nM by MTS assay, which is 5 fold higher than its reported activity in breast cancer cells. WA completely down-regulates HSP90beta, GRP94, and TRAP-1 expression at 250 nM concentration in HNSCC cells at 24 hours treatment. In addition, WA markedly increased HSP70 levels and mildly increased HSP27 levels in a dose-dependent manner at 24 hours treatment. Flow cytometry with Annexin V/PI staining shows that 5 μM WA treatment for 24 hours induced apoptosis in 63% of MDA1986 and 60% of JMAR cells. WA at 5 μM also reduced mitochondrial membrane potential by JC-1 staining with flow cytometry to less than 10% of controls in both JMAR and MDA1986 cells at 24 hours treatment. Conclusions: Withaferin A is a potent novel inhibitor of HSP90 in human HNSCCs. In addition to HSP modulation, its anticancer mechanistic effects involve apoptotic cell death through the mitochondrial pathway. This molecule shows promise for further in vivo studies to establish preclinical proof of concept as a novel anticancer therapy in this disease. No significant financial relationships to disclose.
P1246 : Abdominal ultrasonography guidance reduces the risk of complications and improves success rate after liver biopsy: Results of a meta-analysis comparing the use of ultrasound guidance to the “Blind method”
Authors: A. Garioud, J.-F. Cadranel, J.-B. Nousbaum, A. Smaïl, H. Lison, T. Thévenot, M. Medmoun, D. Belloula, F. Kazerouni, K. Hadj-Nacer, A. Cazier, V. Di Martino
Journal: Journal of Hepatology (2015)
Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab
Authors: Yogin B Patel, Hagop M. Kantarjian, Deborah Thomas, Susan O'Brien, Farhad Ravandi, Guillermo Garcia-Manero, Jorge E. Cortes, Marina Konopleva, Nitin Jain, Rebecca Garris, Jane Autry, Elias Jabbour
Journal: Blood (2015)
Risk Factors and Seroprevalence of Hepatitis E in Pregnant and Non-Pregnant Women in a Southern Region of Brazil
Authors: D.A. Muzzillo, S. Hardtke, R. Rocco, J. Ogata, M. Barbosa, S. Braga, E. Maluf, G. Baldanzi, E. Doi, D. Da Cunha, F. De Oliveira, A. Urbanetz, D. Nascimento, E. Tristão, R. Sbalqueiro, H. Wedemeyer
Journal: Journal of Hepatology (2016)
Prognostic relevance of early response to induction chemotherapy (IC) in locally advanced NSCLC by <sup>18</sup>FDG positron emission tomography (PET)
Authors: C. Hoekstra, E. Smit, J. Vansteenkiste, S. Stroobants, H. V. Tinteren, P. Postmus, A. Lammertsma, O. Hoekstra
Journal: Journal of Clinical Oncology (2004)

7001 Background: In locally advanced NSCLC the performance of response monitoring after combined modality treatment (CMT) using standard CT criteria is limited. Identifying patients with a response to IC in a more reliable way at an early stage of treatment could have major clinical implications. 18FDG PET may be used to assess the effect of IC. The objective of this study was to determine the accuracy of early response measurements using 18FDG PET with respect to survival of stage IIIA-N2 NSCLC patients undergoing CMT. Methods: Consecutive stage IIIA-N2 NSCLC patients who received 3 cycles of platinum based IC were included. A dynamic PET scan was performed prior to the start of IC and after course 1 and 3. CT scan of thorax and upper abdomen was performed before and at the end of IC. PET analysis of the primary tumor was performed by Patlak graphical analysis at 10–60 minutes post injection. The mediastinal lymphnode (MLN) status was assessed visually, and analysed using Kaplan Meier plots and the logrank test (p < 0.05). Cox proportional hazard regression analysis was used to assess the prognostic value of the baseline and %change in 18FDG PET-uptake (MRglu) with respect to survival time. Results: 47 patients (33 men, 14 women, mean age 63 (range 30–81) years) were included. Median follow up is 28 months. MLN status by PET after 1 cycle of IC did not show a significant relation with survival (p=0.74). Baseline Mrglu-value together with the percentage decrease in uptake after one course was related to survival (p=0.05 and p=0.02 respectively in the combined model). The percentage decrease after 3 courses was even more predictive for survival. Conclusions: Response assessment to CMT in stage IIIA-N2 NSCLC using the %change in uptake of 18FDG with PET after 1 and 3 courses of IC is correlated with survival. No significant financial relationships to disclose.
The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment
Authors: Elif Dagdan, Marketa Zaliova, Petra Dörge, Anja Möricke, Martin Zimmermann, Andrea Teigler-Schlegel, Claus R Bartram, Rolf Koehler, Richard Ratei, Wolf-Dieter Ludwig, Julia Alten, Denis Martin Schewe, Christian Kratz, Richard S Houlston, Jean-Pierre Bourquin, Andrea Biondi, Giovanni Cazzaniga, Giuseppe Basso, Geertruy te Kronnie, Marie-Laure Yaspo, Martin Schrappe, Gunnar Cario, Martin Stanulla
Journal: Blood (2014)
Does It Matter?
Authors: Laura McGevna
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia
Authors: Courtney L Jones, Teena Bhatla, Jinhua Wang, Wallace Bourgeois, Bitterman S Danielle, Elizabeth A. Raetz, Debra J. Morrison, David T. Teachey, Garabedian Michael, William L. Carroll
Journal: Blood (2013)
The Effect of Renal or Hepatic Impairment on the Pharmacokinetics of GS-9857, a Pan-Genotypic HCV NS3/4A Protease Inhibitor
Authors: E. Lawitz, T. Marbury, B.J. Kirby, N.T. Au, A. Mathias, L.M. Stamm, H. Wei, K. Sajwani, G. Klein, Ed Gane, R. Robson
Journal: Journal of Hepatology (2016)
Ensuring prudent use of antimicrobials in human medicine in the European Union, 2005
Authors: G Werner, S Bronzwaer
Journal: Eurosurveillance (2007)

The overuse and misuse of antibiotics pose a serious danger to public health by contributing to the development of bacteria resistant to treatment. In 2001, the European Commission launched a strategy to combat the threat of antimicrobial resistance to human, animal and plant health, which includes data collection, surveillance, research, awareness-raising exercises and the phasing out of antibiotics for non-medical use in animals. The Council Recommendation on the prudent use of antibiotics in human medicine adopted in 2002 was a component in this strategy, outlining clear-cut measures in human medicine that EU Member States could take to reduce antimicrobial resistance.
Human Mesenchymal Stem Cells as Precursors of Functional Fibroblastic Reticular Cells: Implications for the Physiopathology of Secondary Lymphoid Organs.
Authors: Karin Tarte, Patricia Ame-Thomas, Hélène Maby, Sylvie Caulet-Maugendre, Rachel Jean, Céline Monvoisin, Thierry Lamy, Thierry Fest
Journal: Blood (2005)
Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition
Authors: Pier Paolo Piccaluga, Maria Rosaria Sapienza, Fuligni Fabio, Agostinelli Claudio, Tripodo Claudio, Righi Simona, Maria Antonella Laginestra, Pileri Alessandro, Rossi Maura, Francesca Ricci, Anna Gazzola, Claudia Mannu, Francesca Ulbar, Mario Arpinati, Marco Paulli, Davide Gibellini, Livio Pagano, Nicola Pimpinelli, Lorenzo Cerroni, Carlo M. Croce, Fabio Facchetti, Stefano A Pileri
Journal: Blood (2013)
P0239 : Tumorigenic potential of Cancer Stem Cells (CSCs) isolated from human cholangiocarcinoma (CCA) subtypes in cirrhotic microenvironment
Authors: V. Cardinale, A. Renzi, G. Carpino, M.C. Bragazzi, A. Torrice, F. Giuliante, A. De Rose, A. Fraveto, P. Onori, C. Napoletano, A. Franchitto, A. Cantafora, G.L. Grazi, N. Caporaso, G. D’Argenio, G. Alpini, L. Reid, E. Gaudio, D. Alvaro
Journal: Journal of Hepatology (2015)
Distinct Cardiac Microvascular Endothelium-specific Gene Signatures in Experimental Pressure-overload Heart Failure
Authors: Sander Trenson, Ann Sophie Walravens, Ellen Caluwé, Sara Vandenwijngaert, Giulia Coppiello, Melissa Swinnen, Jozef Bartunek, Aernout Luttun, Stefan Janssens
Journal: Circulation (2014)